Cellares Expands UW Partnership for Clinical Manufacturing of CRISPR-Edited CAR-T Therapy — Cellares Corporation

Event summary

Cellares and the University of Wisconsin (UW) are expanding their partnership to support clinical production and regulatory advancement of UW’s CRISPR-edited GD2 CAR-T therapy for solid tumors.
The collaboration builds on an initial partnership announced in April 2025, focusing on automating UW’s internally developed CAR-T process.
Cellares will provide manufacturing support using its Cell Shuttle™ and Cell Q™ platforms, along with regulatory expertise for the IND application.
The GD2 CAR-T program targets solid tumors in pediatric and adult patients, initially focusing on high-grade gliomas.

The big picture

This partnership expansion underscores the growing trend of academic institutions leveraging specialized manufacturing organizations to accelerate the development of advanced cell therapies. The integration of automation and regulatory expertise aims to shorten the path from proof-of-concept to clinical trials, addressing a critical bottleneck in the cell therapy space.

What we're watching

Regulatory Milestones: The pace at which the IND application progresses through the FDA, as this will determine the timeline for clinical trials.
Manufacturing Scalability: Whether Cellares’ automated platforms can consistently deliver reliable and reproducible manufacturing outcomes for CRISPR-edited therapies.
Therapeutic Expansion: How the success of the GD2 CAR-T program in high-grade gliomas could inform future studies in other GD2+ cancers like neuroblastoma, osteosarcoma, and melanoma.